

TO:Official fax COMPANY:

**RECEIVED**  
**CENTRAL FAX CENTER****JAN 17 2007****Patent Technology Centers****Facsimile Transmission**

To:                      Name:                      Official fax  
                            Company:  
                            Fax Number:                      571-273-8300  
                            Voice Phone:

From:                      Name:  
                            Official Fax Number:                      (571) 273-8300  
                            Official After Final Fax Number:                      (571) 273-8300  
                            Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:  

---

---

Date and time of transmission: Wednesday, January 17, 2007 1:22:52 PM  
Number of pages including this cover sheet: 03

---

TO: Official fax COMPANY:

01/17/2007 13:03 617-832-7000

FOLEY HOAG LLP

PAGE 01/02



**FOLEY  
HOAG** LLP  
ATTORNEYS AT LAW

**RECEIVED  
CENTRAL FAX CENTER**

**JAN 17 2007**

**Fax**

Date: January 17, 2007

To: Examiner Rita Desai --

Fax #: 571-273-0684

Confirm#: 571-272-0684

Art Unit 1625

Client Matter#: 20473-4802

From: Dana Gordon, PhD

Sender's Number: 1765

User #: 0685

Total Pages Sent (Including Cover Sheet): 2

Office: Boston

**Message**

Applicants: Hoermann, M.Z. *et al.*

Examiner: Desai, R.J.

Application Serial No.: 10/722,114

Art Unit: 1625

Filed: November 25, 2003

Atty. Docket No.: SPV-048.02

Title: 4,4-Disubstituted Piperidines, and Methods of Use Thereof

Dear Examiner Desai:

Please enter the attached Terminal Disclaimer in the above-identified application. The Commissioner is hereby authorized to charge any required fees to our Deposit Account, No. 06-1448; Reference SPV-048.02. Thank you.

Sincerely,

Dana Gordon (Reg. No. 44,719)

**IMPORTANT - PLEASE READ**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

IF THERE ARE ANY PROBLEMS WITH THIS TRANSMISSION PLEASE TELEPHONE THE SENDER.

Seaport World Trade Center West / 155 Seaport Blvd. / Boston, MA 02210-2600 / TEL: 617.832.1000 / FAX: 617.832.7000

Enlow Union 110

BOSTON

WASHINGTON DC

TO:Official fax COMPANY:

01/17/2007 13:03 617-832-7000

**RECEIVED**  
**CENTRAL FAX CENTER**

FOLEY HOAG LLP

PAGE 02/02

**JAN 17 2007**

PTO/SB/26 (10-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING  
REJECTION OVER A PRIOR PATENT**Docket Number (Optional)  
SPV-048.02

In re Application of: Hoemann, M.Z.

Application No.: 10/722,114

Filed: November 25, 2003

For: 4,4-Disubstituted Piperidines, and Methods of Use Thereof

The owner, Sepracor Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,656,953. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.



Signature



Date

Dana M. Gordon (Reg. No. 44,719)

Typed or printed name

- ☐ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

\*Certification under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.